

<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 4 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition or catheterisation and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 4 mg
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.2246
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 8 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition or catheterisation and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 8 mg

Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0003
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Oxybutynin
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition or catheterisation and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Oxybutynin
Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0161

Method	ANCOVA
Confidence interval	